Clinical value of nucleotide analogues for treatment of hepatitis B-related decompensated cirrhosis
-
摘要: 目的探讨接受核苷和核苷酸类药物治疗失代偿期乙型肝炎肝硬化患者的临床效果。方法收集南华医院肝科2007年1月-2013年12月住院的97例失代偿期乙型肝炎肝硬化患者,其中抗病毒组55例,未抗病毒组42例,两组各分为1组(乙型肝炎肝硬化)及2组(乙型肝炎相关性肝癌),抗病毒组中第2组再分为2.1组(发现肝癌前抗病毒)、2.2组(发现肝癌后抗病毒),根据抗病毒时间分为A组(≤24周)、B组(2448周)、C组(>48周)。将各组肝炎病程、肝硬化病程、肝癌病程、生存率、并发症进行比较分析。计量资料两组间比较采用t检验,多组间比较采用单因素方差分析,计数资料组间比较采用χ2检验。结果抗病毒组与未抗病毒组肝硬化病程分别为(53.27±58.16)和(30.76±46.70)个月,3、5年的生存率分别为58.2%、36.4%和33.3%、16.7%,差异均有统计学意义(P值均<0.05),抗病毒组中2.1组与2.2组肝癌病程分别为(3.93±3.39)和(21.58±23.20)个月,差异有统计学意义(P<0.05)。A组、B组、C组肝硬化病程分别为(32.7...
-
关键词:
- 肝炎,乙型 /
- 肝硬化 /
- 抗病毒药 /
- 核酸类,核苷酸类和核苷类
Abstract: Objective To investigate the clinical value of nucleotide analogues for the treatment of hepatitis B- related decompensated cirrhosis. Methods A total of 97 inpatients with hepatitis B- induced decompensated cirrhosis were selected from the Department of Hepatology,Nanhua Hospital,Shanghai,China,from January 2007 to December 2013. There were 55 patients of the antiviral group and 42 patients of the non- antiviral group. Each group was subdivided into groups 1( hepatitis B- related cirrhosis) and 2( hepatitis B- related liver cancer). The antiviral group 2 was further divided into groups 2. 1( antiviral therapy before detection of liver cancer) and 2. 2( antiviral therapy after detection of liver cancer). According to the period of time for antiviral therapy,patients were divided into groups A( ≤24weeks),B( 24- 48 weeks),and C( > 48 weeks). Courses of hepatitis,cirrhosis,and cancer,as well as survival rate and complication incidence,were compared between groups. Continuous data were expressed as the mean ± standard deviation,for which pairwise comparisons were performed using t test and multiple comparisons were performed using one- way ANOVA. Categorical data were expressed as percentage,for which group comparisons were performed using χ2test. Results There were no significant differences between the antiviral and non- antiviral groups regarding course of hepatitis,complication incidence,and 7- year and 9- year survival rates( P > 0. 05). Significant differences existed between the above two groups in course of cirrhosis,53. 27 ± 58. 16 months vs 30. 76 ± 46. 70 months( P < 0. 05); and 3- year and 5- year survival rates,58. 2% and 36. 4% vs 33. 3% and 16. 7%( P < 0. 05). Additionally,course of liver cancer significantly differed between the antiviral groups 2. 1 and 2. 2,3. 93 ± 3. 39 months vs 21. 58 ± 23. 20 months( P < 0. 05). There were no significant differences between groups A,B,and C regarding course of hepatitis,complication incidence,and 9- year survival rate( P > 0. 05). The above three groups of patients showed significant differences in course of cirrhosis,32. 75 ± 61. 32 months vs 25. 86 ± 16. 40 months vs.74. 79 ± 55. 40 months( P < 0. 05); course of hepatitis B- related liver cancer,2. 55 ± 2. 72 months vs 10. 43 ± 7. 25 months vs 17. 71 ±24. 21 months( P < 0. 05); and 3- year,5- year,and 7- year survival rates,( 35. 0%,15. 0%,and 5. 0%) vs( 42. 9%,14. 3%,and14. 3%) vs( 78. 6%,60. 7%,and 35. 7%)( P < 0. 05). Conclusion Antiviral therapy for hepatitis B- related decompensated cirrhosis can prolong the survival time and increase the 3- year and 5- year survival rates in patients with liver cirrhosis and cancer. The curative effect becomes more significant with antiviral therapy over a longer period of time.
本文二维码
计量
- 文章访问数: 174
- HTML全文浏览量: 15
- PDF下载量: 145
- 被引次数: 0